BusinessCognition Therapeutics’ Alzheimer’s Disease Candidate CT1812 Meets Phase 1b/2a Study Objectives: Well Tolerated with Positive Influence on Biomarkers of Synapse RecoveryBy Nasdaq OMXNov 4, 2017, 2:45 PM UTC
BusinessCognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting on November 2nd and 4thBy Nasdaq OMXOct 30, 2017, 12:12 PM UTC
